U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C18H37N5O9
Molecular Weight 467.5152
Optical Activity UNSPECIFIED
Defined Stereocenters 14 / 14
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TOBRAMYCIN

SMILES

C1[C@@]([H])([C@]([H])([C@@]([H])([C@]([H])([C@]1([H])N)O[C@]2([H])[C@@]([H])([C@]([H])([C@@]([H])([C@@]([H])(CO)O2)O)N)O)O)O[C@]3([H])[C@@]([H])(C[C@@]([H])([C@@]([H])(CN)O3)O)N)N

InChI

InChIKey=NLVFBUXFDBBNBW-PBSUHMDJSA-N
InChI=1S/C18H37N5O9/c19-3-9-8(25)2-7(22)17(29-9)31-15-5(20)1-6(21)16(14(15)28)32-18-13(27)11(23)12(26)10(4-24)30-18/h5-18,24-28H,1-4,19-23H2/t5-,6+,7+,8-,9+,10+,11-,12+,13+,14-,15+,16-,17+,18+/m0/s1

HIDE SMILES / InChI

Description
Curator's Comment:: Description was created based on several resourses, including http://www.drugbank.ca/drugs/DB00684

Tobramycin, an aminoglycoside antibiotic obtained from cultures of Streptomyces tenebrarius, it is effective against gram-negative bacteria, especially the pseudomonas species. Tobramycin is used in combination with other antibiotics to treat urinary tract infections, gynecologic infections, peritonitis, endocarditis, pneumonia, bacteremia and sepsis, respiratory infections including those associated with cystic fibrosis, osteomyelitis, and diabetic foot and other soft-tissue infections. It acts primarily by disrupting protein synthesis, leading to altered cell membrane permeability, progressive disruption of the cell envelope, and eventual cell death. Tobramycin has in vitro activity against a wide range of gram-negative organisms including Pseudomonas aeruginosa. Tobramycin binds irreversibly to one of two aminoglycoside binding sites on the 30 S ribosomal subunit, inhibiting bacterial protein synthesis. Tobramycin may also destabilize bacterial memebrane by binding to 16 S 16 S r-RNA. An active transport mechanism for aminoglycoside uptake is necessary in the bacteria in order to attain a significant intracellular concentration of tobramycin. KITABIS PAK (co-packaging of tobramycin inhalation solution and PARI LC PLUS Reusable Nebulizer) is indicated for the management of cystic fibrosis in adults and pediatric patients 6 years of age and older with P. aeruginosa.

CNS Activity

Curator's Comment:: Poor penetrability of tobramycin through the blood-CSF barrier was shown.

Originator

Curator's Comment:: Tobramycin is the generic ingredient in eleven branded drugs marketed by Amneal Pharms, Chiesi Usa Inc, Akorn Inc, Fera Pharms, Pulmoflow Inc, Alcon, Alcon Labs Inc, Bausch And Lomb, Novartis Pharms, Alcon Pharms Ltd, Apotex Inc, Novartis, Teva Pharms Usa, Akorn, Lilly, Mylan Labs Ltd, Hospira, Hikma Maple , X Gen Pharms, Igi Labs Inc, Fresenius Kabi Usa, Apothecon, Watson Labs Inc, and Xellia Pharms Aps, and is included in forty-five NDAs. Nebramycin, an antibiotic complex of at least seven factors, was first described in 1967 by Stark et al.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
9.0 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
TOBREX

Approved Use

external infections of the eye

Launch Date

3.45427214E11
Primary
KITABIS PAK

Approved Use

cystic fibrosis

Launch Date

1.39216316E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
3.7 μg/mL
80 mg single, intramuscular
dose: 80 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
TOBRAMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
814 μg/mL
300 mg single, respiratory
dose: 300 mg
route of administration: Respiratory
experiment type: SINGLE
co-administered:
TOBRAMYCIN unknown
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
11.6 μg × h/mL
80 mg single, intramuscular
dose: 80 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
TOBRAMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.6 h
80 mg single, intramuscular
dose: 80 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
TOBRAMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
4.4 h
300 mg single, respiratory
dose: 300 mg
route of administration: Respiratory
experiment type: SINGLE
co-administered:
TOBRAMYCIN unknown
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
100%
300 mg single, respiratory
dose: 300 mg
route of administration: Respiratory
experiment type: SINGLE
co-administered:
TOBRAMYCIN unknown
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
12 mg/kg 1 times / day multiple, intravenous (mean)
Highest studied dose
Dose: 12 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 12 mg/kg, 1 times / day
Sources:
unhealthy, 2 months - 27 years
Health Status: unhealthy
Condition: cystic fibrosis
Age Group: 2 months - 27 years
Sources:
300 mg 2 times / day multiple, respiratory
Recommended
Dose: 300 mg, 2 times / day
Route: respiratory
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, >6 years
n = 190
Health Status: unhealthy
Age Group: >6 years
Sex: M+F
Population Size: 190
Sources:
Other AEs: Forced expiratory volume decreased, Rales...
Other AEs:
Forced expiratory volume decreased (31%)
Rales (19%)
Red blood cell sedimentation rate increased (8%)
Dysphonia (6%)
Wheezing (5%)
Sources:
3 mg 3 times / day multiple, ophthalmic
Recommended
Dose: 3 mg, 3 times / day
Route: ophthalmic
Route: multiple
Dose: 3 mg, 3 times / day
Sources:
unhealthy, adult
Other AEs: Hypersensitivity, Eyelids itchy sensation of...
Other AEs:
Hypersensitivity
Eyelids itchy sensation of
Swelling
Redness of eyelid conjunctiva
Sources:
1.5 mg/kg 3 times / day multiple, intramuscular
Dose: 1.5 mg/kg, 3 times / day
Route: intramuscular
Route: multiple
Dose: 1.5 mg/kg, 3 times / day
Sources:
unhealthy, adult
n = 28
Health Status: unhealthy
Condition: gram-negative bacilli infection
Age Group: adult
Population Size: 28
Sources:
2 mg/kg single, intraperitoneal
Dose: 2 mg/kg
Route: intraperitoneal
Route: single
Dose: 2 mg/kg
Sources:
unhealthy, adult
n = 5
Health Status: unhealthy
Condition: end stage renal disease
Age Group: adult
Population Size: 5
Sources:
AEs

AEs

AESignificanceDosePopulation
Rales 19%
300 mg 2 times / day multiple, respiratory
Recommended
Dose: 300 mg, 2 times / day
Route: respiratory
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, >6 years
n = 190
Health Status: unhealthy
Age Group: >6 years
Sex: M+F
Population Size: 190
Sources:
Forced expiratory volume decreased 31%
300 mg 2 times / day multiple, respiratory
Recommended
Dose: 300 mg, 2 times / day
Route: respiratory
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, >6 years
n = 190
Health Status: unhealthy
Age Group: >6 years
Sex: M+F
Population Size: 190
Sources:
Wheezing 5%
300 mg 2 times / day multiple, respiratory
Recommended
Dose: 300 mg, 2 times / day
Route: respiratory
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, >6 years
n = 190
Health Status: unhealthy
Age Group: >6 years
Sex: M+F
Population Size: 190
Sources:
Dysphonia 6%
300 mg 2 times / day multiple, respiratory
Recommended
Dose: 300 mg, 2 times / day
Route: respiratory
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, >6 years
n = 190
Health Status: unhealthy
Age Group: >6 years
Sex: M+F
Population Size: 190
Sources:
Red blood cell sedimentation rate increased 8%
300 mg 2 times / day multiple, respiratory
Recommended
Dose: 300 mg, 2 times / day
Route: respiratory
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, >6 years
n = 190
Health Status: unhealthy
Age Group: >6 years
Sex: M+F
Population Size: 190
Sources:
Eyelids itchy sensation of
3 mg 3 times / day multiple, ophthalmic
Recommended
Dose: 3 mg, 3 times / day
Route: ophthalmic
Route: multiple
Dose: 3 mg, 3 times / day
Sources:
unhealthy, adult
Hypersensitivity
3 mg 3 times / day multiple, ophthalmic
Recommended
Dose: 3 mg, 3 times / day
Route: ophthalmic
Route: multiple
Dose: 3 mg, 3 times / day
Sources:
unhealthy, adult
Redness of eyelid conjunctiva
3 mg 3 times / day multiple, ophthalmic
Recommended
Dose: 3 mg, 3 times / day
Route: ophthalmic
Route: multiple
Dose: 3 mg, 3 times / day
Sources:
unhealthy, adult
Swelling
3 mg 3 times / day multiple, ophthalmic
Recommended
Dose: 3 mg, 3 times / day
Route: ophthalmic
Route: multiple
Dose: 3 mg, 3 times / day
Sources:
unhealthy, adult
PubMed

PubMed

TitleDatePubMed
Synthesis and anti-HIV activity of guanidinoglycosides.
2000 Dec 29
Outbreak caused by tobramycin-resistant Pseudomonas aeruginosa in a bone marrow transplantation unit.
2001
Comparative review of topical ophthalmic antibacterial preparations.
2001
Infectious crystalline keratopathy in an immunosuppressed patient.
2001 Apr
[Mupirocin resistant MRSA in Japan].
2001 Apr
Effect of size and disease on estimated deposition of drugs administered using jet nebulization in children with cystic fibrosis.
2001 Apr
Serratia Marcescens corneal ulcer as a complication of orthokeratology.
2001 Aug
Selective decontamination of the digestive tract in severely burned pediatric patients.
2001 Aug
[Antibiotic resistance of Staphylococcus aureus in urban experience: 6 month study in Aquitaine].
2001 Feb
Randomized controlled monocentric comparison of once daily ceftriaxone with tobramycin and cefotaxime three times daily with tobramycin in neutropenic fever.
2001 Feb
[Effect of subinhibitory levels of aminoglycosides and fluoroquinolines on hydrophobicity and motility of Serratia marcescens].
2001 Feb
Role of bronchoalveolar lavage in immunocompromised patients with pneumonia treated with a broad spectrum antibiotic and antifungal regimen.
2001 Feb
Changes in strategies for optimal antibacterial therapy in cystic fibrosis.
2001 Feb
[Adverse effects of transrectal prostatic biopsy. Analysis of 303 procedures].
2001 Jan
[Pacemaker-cable endocarditis and spondylodiscitis caused by Citrobacter koseri. Conservative treatment].
2001 Jan
Gut decontamination of critically ill patients reduces Helicobacter pylori acquisition by intensive care nurses.
2001 Jan
A case-control study of the relationships among silica exposure, gastric cancer, and esophageal cancer.
2001 Jan
Applications of a copper microparticle-modified carbon fiber microdisk array electrode for the simultaneous determination of aminoglycoside antibiotics by capillary electrophoresis.
2001 Jan 5
Aminoglycosides in cystic fibrosis: a descriptive study of current practice in Australia.
2001 Jan-Feb
Perioperative microbiologic profile of the conjunctiva in photorefractive keratectomy.
2001 Jan-Feb
Recent advances in cystic fibrosis.
2001 Jul
Antibiotic therapy in intra-abdominal infections--a review on randomised clinical trials.
2001 Jul 30
Some 3-thioxo/alkylthio-1,2,4-triazoles with a substituted thiourea moiety as possible antimycobacterials.
2001 Jul 9
Tobramycin (Cystic Fibrosis Foundation/PathoGenesis).
2001 Jun
Clinical observation and treatment of leptospirosis.
2001 Jun
Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia.
2001 Jun
Ultraviolet recall-like phenomenon occurring after piperacillin, tobramycin, and ciprofloxacin therapy.
2001 Jun
Mucositis reduction by selective elimination of oral flora in irradiated cancers of the head and neck: a placebo-controlled double-blind randomized study.
2001 Jun 1
Risk of endotoxemia during the initial phase of gut decontamination with antimicrobial agents.
2001 Mar
Effect of some fractions of alveolar surfactant (phospholipids and SP-A) on the bactericidal activity of different antimicrobials against some respiratory pathogens.
2001 Mar
Aminoglycoside ototoxicity.
2001 Mar
[Effect of tobramycin with topical diclofenac on arachidonic acid in endotoxin-induced uveitis].
2001 Mar
Cystic fibrosis.
2001 Mar
Kinetic and mutagenic characterization of the chromosomally encoded Salmonella enterica AAC(6')-Iy aminoglycoside N-acetyltransferase.
2001 Mar 27
Management of corneal epithelial defects following laser in situ keratomileusis.
2001 Mar-Apr
Natural antibiotic susceptibility of recently established coryneform bacteria.
2001 May
[Functional characterization of a multiple-antibiotic resistant plasmid from clinical isolates of methicillin-resistant Staphylococcus aureus].
2001 May
Prescribing patterns of optometrists newly licensed in therapeutic drug use in New York State.
2001 May
Clinical applications of a novel sustained-release injectable drug delivery system: DepoFoam technology.
2001 May-Jun
A comparison of cortisporin and ciprofloxacin otic drops as prophylaxis against post-tympanostomy otorrhea.
2001 Nov 1
Serum and lower respiratory tract drug concentrations after tobramycin inhalation in young children with cystic fibrosis.
2001 Oct
Genotypic characterization of Pseudomonas aeruginosa strains recovered from patients with cystic fibrosis after initial and subsequent colonization.
2001 Oct
High-rising terminals and fall-rise tunes in Australian English.
2001 Oct-Dec
The changing nature of aminoglycoside resistance mechanisms and prevalence of newly recognized resistance mechanisms in Turkey.
2001 Sep
Reduction in gram-positive pneumonia and antibiotic consumption following the use of a SDD protocol including nasal and oral mupirocin.
2001 Sep
Defining a pulmonary exacerbation in cystic fibrosis.
2001 Sep
A simple infection model using pre-colonized implants to reproduce rat chronic Staphylococcus aureus osteomyelitis and study antibiotic treatment.
2001 Sep
Treatment of chronic rhinosinusitis refractory to other treatments with topical antibiotic therapy delivered by means of a large-particle nebulizer: results of a controlled trial.
2001 Sep
Microbiological and immunologic considerations with aerosolized drug delivery.
2001 Sep
Administration of aerosolized antibiotics in cystic fibrosis patients.
2001 Sep
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment:: Tobramycin does not pass the gastro-intestinal tract, so for systemic use it can only be given intravenously or intramuscularly http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/063111s014lbl.pdf. Dosage is different for different infections. Ophthalmic route of administration is also possible, as indicated here http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails or for TOBREX http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050541s024lbl.pdf
KITABIS PAK is a co-packaging of tobramycin inhalation solution ampules with a PARI LC PLUS Reusable Nebulizer. Administer as follows: One single-use ampule (300 mg /5 mL) of tobramycin inhalation solution twice a day by oral inhalation in alternating periods of 28 days on drug, followed by 28 days off drug. The 300 mg/5mL dose of tobramycin inhalation solution is the same for all patients regardless of age or weight. The doses should be taken as close to 12 hours apart as possible; they should not be taken less than 6 hours apart.
Route of Administration: Respiratory
In Vitro Use Guide
Curator's Comment:: Low dose tobramycin (4 ug/ml) as a single agent was bactericidal against only 16% of Pseudomonas aeruginosa isolates; however, 72% of isolates were killed with high-dose tobramycin (200 ug/ml).
High-dose tobramycin (200 ug/ml) killed 72% of Pseudomonas aeruginosa isolates
Name Type Language
TOBRAMYCIN
EP   HSDB   INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
TOBRAMYCIN [ORANGE BOOK]
Common Name English
TOBRAMYCIN [USP]
Common Name English
TOBRASONE COMPONENT TOBRAMYCIN
Common Name English
ZYLET COMPONENT TOBRAMYCIN
Common Name English
TOBRAMYCIN COMPONENT OF ZYLET
Common Name English
TOBRAMYCIN [EP MONOGRAPH]
Common Name English
TOBREX
Brand Name English
TOBRAMYCIN [HSDB]
Common Name English
TOBRAMYCIN [INN]
Common Name English
NEBRAMYCIN VI
Common Name English
TOBRAMYCIN [MI]
Common Name English
TOBRADEX ST COMPONENT TOBRAMYCIN
Common Name English
AKTOB
Brand Name English
NEBRAMYCIN FACTOR 6
Common Name English
TOBRAMYCIN [VANDF]
Common Name English
47663
Code English
TOBRAMYCIN COMPONENT OF TOBRADEX
Common Name English
KITABIS PAK
Brand Name English
TOBRAMYCIN COMPONENT OF TOBRADEX ST
Common Name English
D-STREPTAMINE, O-3-AMINO-3-DEOXY-.ALPHA.-D-GLUCOPYRANOSYL-(1->6)-O-(2,6-DIAMINO-2,3,6-TRIDEOXY-.ALPHA.-D-RIBO-HEXOPYRANOSYL-(1->4))-2-DEOXY-
Common Name English
TOBRAMYCIN [WHO-DD]
Common Name English
VANTOBRA
Brand Name English
O-3-AMINO-3-DEOXY-.ALPHA.-D-GLUCOPYRANOSYL-(1->4)-O-(2,6-DIAMINO-2,3,6-TRIDEOXY-.ALPHA.-D-RIBO-HEXOPYRANOSYL-(1.ALPHA.6))-2-DEOXY-L-STREPTAMINE
Common Name English
TOBRAMYCIN COMPONENT OF TOBRASONE
Common Name English
TOBI PODHALER
Brand Name English
NSC-180514
Code English
TOBRAMYCIN [USAN]
Common Name English
TOBRAMYCIN [MART.]
Common Name English
TOBRAMYCIN [USP-RS]
Common Name English
TOBI
Brand Name English
TOBRADEX COMPONENT TOBRAMYCIN
Common Name English
Classification Tree Code System Code
NDF-RT N0000007853
Created by admin on Fri Jun 25 21:19:20 UTC 2021 , Edited by admin on Fri Jun 25 21:19:20 UTC 2021
NCI_THESAURUS C2363
Created by admin on Fri Jun 25 21:19:20 UTC 2021 , Edited by admin on Fri Jun 25 21:19:20 UTC 2021
WHO-ATC S01AA12
Created by admin on Fri Jun 25 21:19:20 UTC 2021 , Edited by admin on Fri Jun 25 21:19:20 UTC 2021
WHO-VATC QJ01GB01
Created by admin on Fri Jun 25 21:19:20 UTC 2021 , Edited by admin on Fri Jun 25 21:19:20 UTC 2021
EU-Orphan Drug EU/3/06/366
Created by admin on Fri Jun 25 21:19:20 UTC 2021 , Edited by admin on Fri Jun 25 21:19:20 UTC 2021
FDA ORPHAN DRUG 84494
Created by admin on Fri Jun 25 21:19:20 UTC 2021 , Edited by admin on Fri Jun 25 21:19:20 UTC 2021
LIVERTOX 972
Created by admin on Fri Jun 25 21:19:20 UTC 2021 , Edited by admin on Fri Jun 25 21:19:20 UTC 2021
WHO-VATC QS01AA12
Created by admin on Fri Jun 25 21:19:20 UTC 2021 , Edited by admin on Fri Jun 25 21:19:20 UTC 2021
FDA ORPHAN DRUG 271908
Created by admin on Fri Jun 25 21:19:20 UTC 2021 , Edited by admin on Fri Jun 25 21:19:20 UTC 2021
FDA ORPHAN DRUG 278009
Created by admin on Fri Jun 25 21:19:20 UTC 2021 , Edited by admin on Fri Jun 25 21:19:20 UTC 2021
CFR 21 CFR 862.3900
Created by admin on Fri Jun 25 21:19:20 UTC 2021 , Edited by admin on Fri Jun 25 21:19:20 UTC 2021
WHO-ATC J01GB01
Created by admin on Fri Jun 25 21:19:20 UTC 2021 , Edited by admin on Fri Jun 25 21:19:20 UTC 2021
NDF-RT N0000175477
Created by admin on Fri Jun 25 21:19:20 UTC 2021 , Edited by admin on Fri Jun 25 21:19:20 UTC 2021
FDA ORPHAN DRUG 281709
Created by admin on Fri Jun 25 21:19:20 UTC 2021 , Edited by admin on Fri Jun 25 21:19:20 UTC 2021
EMA ASSESSMENT REPORTS VANTOBRA (AUTHORIZED: CYSTIC FIBROSIS)
Created by admin on Fri Jun 25 21:19:20 UTC 2021 , Edited by admin on Fri Jun 25 21:19:20 UTC 2021
EMA ASSESSMENT REPORTS TOBI PODHALER (AUTHORIZED: CYSTIC FIBROSIS)
Created by admin on Fri Jun 25 21:19:20 UTC 2021 , Edited by admin on Fri Jun 25 21:19:20 UTC 2021
FDA ORPHAN DRUG 121098
Created by admin on Fri Jun 25 21:19:20 UTC 2021 , Edited by admin on Fri Jun 25 21:19:20 UTC 2021
Code System Code Type Description
CAS
32986-56-4
Created by admin on Fri Jun 25 21:19:20 UTC 2021 , Edited by admin on Fri Jun 25 21:19:20 UTC 2021
PRIMARY
EPA CompTox
32986-56-4
Created by admin on Fri Jun 25 21:19:20 UTC 2021 , Edited by admin on Fri Jun 25 21:19:20 UTC 2021
PRIMARY
LACTMED
Tobramycin
Created by admin on Fri Jun 25 21:19:20 UTC 2021 , Edited by admin on Fri Jun 25 21:19:20 UTC 2021
PRIMARY
NCI_THESAURUS
C62082
Created by admin on Fri Jun 25 21:19:20 UTC 2021 , Edited by admin on Fri Jun 25 21:19:20 UTC 2021
PRIMARY
INN
2990
Created by admin on Fri Jun 25 21:19:20 UTC 2021 , Edited by admin on Fri Jun 25 21:19:20 UTC 2021
PRIMARY
PUBCHEM
36294
Created by admin on Fri Jun 25 21:19:20 UTC 2021 , Edited by admin on Fri Jun 25 21:19:20 UTC 2021
PRIMARY
FDA UNII
VZ8RRZ51VK
Created by admin on Fri Jun 25 21:19:20 UTC 2021 , Edited by admin on Fri Jun 25 21:19:20 UTC 2021
PRIMARY
EVMPD
SUB11134MIG
Created by admin on Fri Jun 25 21:19:20 UTC 2021 , Edited by admin on Fri Jun 25 21:19:20 UTC 2021
PRIMARY
MESH
D014031
Created by admin on Fri Jun 25 21:19:20 UTC 2021 , Edited by admin on Fri Jun 25 21:19:20 UTC 2021
PRIMARY
ECHA (EC/EINECS)
251-322-5
Created by admin on Fri Jun 25 21:19:20 UTC 2021 , Edited by admin on Fri Jun 25 21:19:20 UTC 2021
PRIMARY
ChEMBL
CHEMBL1747
Created by admin on Fri Jun 25 21:19:20 UTC 2021 , Edited by admin on Fri Jun 25 21:19:20 UTC 2021
PRIMARY
DRUG CENTRAL
2684
Created by admin on Fri Jun 25 21:19:20 UTC 2021 , Edited by admin on Fri Jun 25 21:19:20 UTC 2021
PRIMARY
RXCUI
10627
Created by admin on Fri Jun 25 21:19:20 UTC 2021 , Edited by admin on Fri Jun 25 21:19:20 UTC 2021
PRIMARY RxNorm
USP_CATALOG
1667508
Created by admin on Fri Jun 25 21:19:20 UTC 2021 , Edited by admin on Fri Jun 25 21:19:20 UTC 2021
PRIMARY USP-RS
WIKIPEDIA
TOBRAMYCIN
Created by admin on Fri Jun 25 21:19:20 UTC 2021 , Edited by admin on Fri Jun 25 21:19:20 UTC 2021
PRIMARY
MERCK INDEX
M10917
Created by admin on Fri Jun 25 21:19:20 UTC 2021 , Edited by admin on Fri Jun 25 21:19:20 UTC 2021
PRIMARY Merck Index
HSDB
3259
Created by admin on Fri Jun 25 21:19:20 UTC 2021 , Edited by admin on Fri Jun 25 21:19:20 UTC 2021
PRIMARY
DRUG BANK
DB00684
Created by admin on Fri Jun 25 21:19:20 UTC 2021 , Edited by admin on Fri Jun 25 21:19:20 UTC 2021
PRIMARY